ANDA 73459, held by Omnivium Pharmaceuticals. Clemastine Fumarate.
As of Nov 21, 2026, ANDA 73459 (Clemastine Fumarate), held by Omnivium Pharmaceuticals, was first approved by FDA on Oct 31, 1993, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 1993 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clemastine Fumarate2.68MG · tablet;oral | Clemastine Fumarate | Discontinued |
| Dec 16, 2002 | Supplement 11Manufacturing | Approved | None posted |
| May 13, 2002 | Supplement 10Manufacturing | Approved | None posted |
| Sep 4, 2001 | Supplement 5Manufacturing | Approved | None posted |
| Aug 7, 2001 | Supplement 9Manufacturing | Approved | None posted |
| Jan 2, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Dec 29, 2000 | Supplement 7Manufacturing | Approved | None posted |
| Nov 30, 2000 | Supplement 6Manufacturing | Approved | None posted |
| May 5, 1999 | Supplement 3Manufacturing | Approved | None posted |
| Mar 27, 1998 | Supplement 2Manufacturing | Approved | None posted |
| Aug 15, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Oct 31, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters